NHI.no
Annonse
Informasjon

Hormonbehandling i og etter overgangsalderen

Ved overgangsalderen stanser produksjonen av østrogen (og progesteron) i eggstokkene, og dette kan føre til overgangsplager. Tilførsel av østrogen - hormonbehandling - kan stoppe disse plagene, men det kan også øke risikoen for blant annet hjerneslag og brystkreft.

Hormonbehandling kan lindre overgangsplager, men det kan også gi en liten økning i risiko for alvorlige bivirkninger.

Sist oppdatert:

6. sep. 2021

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Overgangsalder (klimakteriet) . Referanselisten for dette dokumentet vises nedenfor

  1. Øverlie I et al. Overgangsalder (menopause). Norsk gynekologisk forening Veileder i gynekologi (2021). ePub. ISBN 978-82-692382-1-1. Siden besøkt 10.05.2023 www.legeforeningen.no
  2. Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S. Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women's Cohort study. Maturitas, 2011; 70 (4): 383–390. pmid:10.1016/j.maturitas.2011.09.011
  3. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015. pmid: 25686030 PubMed
  4. Kinney A, Kline J, Levin B. Alcohol, caffeine and smoking in relation to age at menopause. Maturitas. 2006;54:27-38. PMID: 16260101 PubMed
  5. Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014 Oct;43(5):1542-62. Epub 2014 Apr 26. PMID: 24771324 PubMed
  6. Duffy OK, Iversen L, Hannaford PC. Factors associated with reporting classic menopausal symptoms differ. Climacteric 2013; 16: 240-51. pmid:22992029 PubMed
  7. Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric. 2018 Apr;21(2):96-100. Epub 2018 Feb 2. PMID: 29390899 PubMed
  8. Øverlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas. 2002 Jan 30;41(1):69-77. PMID: 11809345. PubMed
  9. Jacob LE, Krishnan M, Mathew A et al. Xerostomia - A Comprehensive Review with a Focus on Mid-Life Health. J Midlife Health. 2022 Apr-Jun;13(2):100-106. Epub 2022 Sep 16. PMID: 36276621 PubMed
  10. Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 10.05.2023 www.legeforeningen.no
  11. Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved utvalgte kliniske problemstillinger. Siden besøkt 10.05.2023
  12. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons US Preventive Services Task Force Recommendation Statement. JAMA 2022; 328: 1740-1746. OMID: 36318127
  13. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68. pmid: 24084921 PubMed
  14. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD004143. The Cochrane Library
  15. Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016 May;65(5):794-803. Epub 2016 Jan 12. PMID: 27085786 PubMed
  16. Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2: e1917789. pmid:31860103 PubMed
  17. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD006108. pmid: 25431132 PubMed
  18. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD000333. DOI: 10.1002/14651858.CD000333.pub2 DOI
  19. Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018 Apr;21(2):111-122. Epub 2018 Jan 31. PMID: 29384406 PubMed
  20. Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012 Aug 15;8 pmid: 22895916 PubMed
  21. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500..CD001500.pub3.pmid: 27577677 PubMed
  22. Bhupathiraju SN, Grodstein M, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 2018. pmid:30562320 PubMed
  23. Islam RM, Bell RJ, Green S et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019; 25: S2213-8587. pmid:31353194 PubMed
  24. Johansen N, Lindén Hirschberg A, Moen MH. The role of testosterone in menopausal hormone treatment. What is the evidence? Acta Obstet Gynecol Scand. 2020 Aug;99(8):966-969. Epub 2020 Mar 2. PMID: 32027015.
  25. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10:CD008536. Epub ahead of print. pmid: 27733017 PubMed
  26. Moen MH, Johansen N. Testosteronbehandling til kvinner. Tidsskr Nor Laegeforen. 2023 Mar 8;143(4). Norwegian. PMID: 36919306 PubMed
  27. Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359: 2005-17. PMID: 18987368 PubMed
  28. Davis SR, Baber R, Panay N et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric 2019. epub 2:1-6. pmid:31474158 PubMed
  29. Elraiyah T, Sonbol MB, Wang Z et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99(10): 3543-50. pmid:25279572 PubMed
  30. Gaudard AIS, Silva de Souza S et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD010407 pmid: 27479272 PubMed
  31. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Library, Jan 21, 2009. pmid: 15495039 PubMed
  32. Lokkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017; 48: 2266-9. PMID: 28626058 PubMed
  33. Gartlehner G, Patel SV, Reddy S, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2022: 328: 1747-1765. pmid:36318128 PubMed
  34. Haimov-Kochman R, Barak-Glantz E, Arbel R et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006 May-Jun;13(3):370-6. PMID: 16735933.
  35. Bonga KN, Mishra A, Maiti R, et al . Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis. Obstet Gynecol 2024. pmid:38227939 PubMed
  36. Morga A, Ajmera M, Gao E, et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause 2024; 31(1): 68-76. pmid: 38016166 PubMed
  37. Shams T, Firwana B, Habib F, et al. SSRIs for Hot Flashes: A systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2013 Jul 26 PMID: 23888328 PubMed
  38. Sarri G, Pedder H, Dias S, Guo Y1, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute of Health and Care Excellence guideline on menopause. BJOG 2017. pmid:28276200 PubMed
  39. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011;12:570-7. PubMed
  40. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. JAMA 2006; 295: 2057-71. pmid: 16670414 PubMed
  41. Leon-Ferre RA, Novotny PJ, Wolfe EG et al. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz088. PMID: 32337497 PubMed
  42. O'Connor KA, Ferrel R, Brindle E, et al. Progesterone and ovulation across stages of the transition to menopause. Menopause 2009; 16: 1178-87. pmid: 19568209 PubMed
  43. Norsk Endokrinologisk Forening. Osteoporose. I Nasjonal veileder i endokrinologi. Publisert 26.02.2020. Siden lest 20.10.2020. www.prosedyrer.no
  44. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women study. Lancet 2003; 362: 419-27. PubMed
  45. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157: 1-10. pmid: 22786830 PubMed
  46. Mosekilde L, Beck-Nielsen H, Sørensen OH et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-93. pmid:11063900 PubMed
  47. Pinkerton JAV, Aguirre FS, Blake J et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017 Jul 1;24(7):728-753. PMID: 28650869 PubMed
  48. Rossouw JE, Anderson GL, Prentice RLet al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. PMID: 12117397.
  49. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350:1047-59. PubMed
  50. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women`s Health Initiative observational study. J Natl Cancer Inst 2013; 105: 526-35. pmid: 23543779 PubMed
  51. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ 2020. PMID: 33115755 PubMed
  52. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA 2017; 318: 927-38. pmid:28898378 PubMed
  53. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019. pmid:31474332 PubMed
  54. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. pmid: 25684585 PubMed
  55. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's health initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374: 1243-51. PubMed
  56. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012. pmid:23048011 PubMed
  57. Anderson GL, Limacher M, Assaf AR et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701-12. PMID: 15082697. PubMed
  58. Renoux C, Dellàniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010; 340: c2519. pmid: 20525678 PubMed
  59. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormon therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340-5. PubMed
  60. Liu B, Beral V, Balkwill A et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386. PubMed
  61. Moro E, Degli Esposti E, Borghese G et al. The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature. Medicina (Kaunas). 2019 Aug 30;55(9):549. PMID: 31480288 PubMed
  62. Moen MH, Rees M, Brincat M et al. European Menopause and Andropause Society. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas. 2010 Sep;67(1):94-7. PMID: 20627430. PubMed
  63. Attarian H, Hachul H, Guttuso T, Phillips B. Treatment of chronic insomnia disorder in menopause: evaluation of literature. Menopause 2015; 22: 674-84. pmid:25349958 PubMed
  64. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD003122. DOI: 10.1002/14651858.CD003122.pub2 DOI
  65. Sung Y-F, Tsai C-T, Kuo C-Y, et al. Use of hormone replacement therapy and risk of dementia: A nationwide cohort study. Neurology 2022. pmid:36240091 PubMed
  66. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F et al. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019; 364: I665. pmid:30842086 PubMed
  67. Holmberg L, Iversen OE, Rudenstam CM, et al. HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82. PubMed
  68. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis . BMJ 2008; 336: 1227-31. PubMed
  69. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 49-57. PubMed
  70. Lund KS, Siersma V, Brodersen J, Waldorff FB. Efficacy of a standardised acupuncture approach for women with bothersome menopausal symptoms: a pragmatic randomised study in primary care (the ACOM study). BMJ Open 2019; 9: e023637. pmid:30782712 PubMed
  71. Dodin S, Blanchet C, Marc I et al. Acupuncture for menopausal hot flushes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD007410. DOI: 10.1002/14651858.CD007410.pub2 DOI
  72. Guthrie KA, LaCroix AZ, Ensrud KE, et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol 2015; 126: 413-22. pmid: 26241433 PubMed
  73. Sternfeld B et al. Efficacy of exercise for menopausal symptoms: A randomized controlled trial. Menopause 2014; 21:330. pmid: 23899828 PubMed
  74. Daley A, Thomas A, Roalfe A, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG. 2014 PMID: 25516405 PubMed
  75. Newton KM, et al. Efficacy of yoga for vasomotor symptoms: A randomized controlled trial. Menopause 2014; 21:339. pmid: 24045673 PubMed
  76. Cohen LS, et al. Efficacy of omega-3 for vasomotor symptoms treatment: A randomized controlled trial. Menopause 2014; 21:347. pmid: 23982113 PubMed
  77. Zhu X, Liew Y, Liu ZL. Chinese herbal medicine for menopausal symptoms. Cochrane Database Syst Rev. 2016 Mar 15;3: pmid: 26976671 PubMed
  78. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD001395. pmid:24323914 PubMed
  79. Franco OH, Chowdhury R, Troup J, et al. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA. 2016; 315: 2554-63. pmid: 27327802 PubMed
  80. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007244. pmid: 22972105 PubMed
  81. Jang YC, Leung CY, Huang HL. Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon Dioxide Laser vs Vaginal Estrogen Therapy: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022 Sep 1;5(9):e2232563. PMID: 36129710. PubMed
  82. Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA 2019. doi:10.1001/jama.2019.19191 DOI
  83. Jean Shin, Kyungdo Han, Jin Hyung Jung et al. Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study, European Heart Journal, 2022;, ehac364, https://doi.org/10.1093/eurheartj/ehac364
Annonse
Annonse